Nonpharmacological Interventions for the Treatment of Cardiometabolic Risk Factors in People With Schizophrenia-A Systematic ReviewFRONTIERS IN PSYCHIATRYIF3.22019-08-1623OAAI
12-week double-blind randomized multicenter study of efficacy and safety of agomelatine (25-50 mg/day) versus escitalopram (10-20 mg/day) in out-patients with severe generalized anxiety disorderEUROPEAN NEUROPSYCHOPHARMACOLOGYIF6.72018-08-0124PREAI
PREVALENCE OF SEXUAL DYSFUNCTIONS IN PATIENTS WITH INSOMNIA AND HYPERSOMNIASLEEP MEDICINEIF3.42017-12-010PREAI
Efficacy and safety of agomelatine 25-50 mg/day versus escitalopram 10-20 mg/day in severe generalized anxiety disorderEUROPEAN NEUROPSYCHOPHARMACOLOGYIF6.72017-10-010PREAI
A blind spot on the global mental health map: a scoping review of 25 years' development of mental health care for people with severe mental illnesses in central and eastern EuropeLANCET PSYCHIATRYIF24.82017-08-01107OAAI
Effects of cognitive remediation therapy versus other interventions on cognitive functioning in schizophrenia inpatients认知矫正疗法与其他干预措施对住院精神分裂症患者认知功能的影响NEUROPSYCHOLOGICAL REHABILITATIONIF1.92017-05-0118PREAI
SEXUAL DYSFUNCTIONS IN PATIENTS REFERRED TO SLEEP DISORDERS CENTERJOURNAL OF SEXUAL MEDICINEIF3.32017-05-011PREAI
lEfficacy and safety of agomelatine (10 or 25 mg/day) in non-depressed out-patients with generalized anxiety disorder: A 12-week, double-blind, placebo-controlled studyEUROPEAN NEUROPSYCHOPHARMACOLOGYIF6.72017-05-0130OAAI
Efficacy and safety of 2 doses of agomelatine (10 mg/day or 25 mg/day) versus placebo in generalized anxiety disorderEUROPEAN NEUROPSYCHOPHARMACOLOGYIF6.72016-10-010PREAI
Biological markers for anxiety disorders, OCD and PTSD: A consensus statement. Part II: Neurochemistry, neurophysiology and neurocognitionWORLD JOURNAL OF BIOLOGICAL PSYCHIATRYIF3.82016-07-15139OAAI
Biological markers for anxiety disorders, OCD and PTSD - a consensus statement. Part I: Neuroimaging and geneticsWORLD JOURNAL OF BIOLOGICAL PSYCHIATRYIF3.82016-07-12113PREAI
Consensus paper of the WFSBP Task Force on Biological Markers: Criteria for biomarkers and endophenotypes of schizophrenia part II: Cognition, neuroimaging and geneticsWORLD JOURNAL OF BIOLOGICAL PSYCHIATRYIF3.82016-06-1726PREAI
Consensus paper of the WFSBP Task Force on Biological Markers: Criteria for biomarkers and endophenotypes of schizophrenia part I: NeurophysiologyWORLD JOURNAL OF BIOLOGICAL PSYCHIATRYIF3.82015-07-2737PREAI
Functional polymorphism of matrix metalloproteinase-9 (MMP9) gene is not associated with schizophrenia and with its deficit subtypePHARMACOLOGICAL REPORTSIF3.82015-06-0116PREAI
The Polish Academic Version of the MATRICS Consensus Cognitive Battery (MCCB): Evaluation of Psychometric PropertiesPSYCHIATRIC QUARTERLYIF2.92015-01-2015OAAI
Age or age at onset? Which of them really matters for neuro and social cognition in schizophrenia?PSYCHIATRY RESEARCHIF3.92015-01-0134PREAI
Daytime sleepiness and EEG abnormalities in patients treated with second generation antipsychotic agentsPHARMACOLOGICAL REPORTSIF3.82014-12-015PREAI
Electroencephalographic theta activity and cognition in schizophrenia: Preliminary resultsWORLD JOURNAL OF BIOLOGICAL PSYCHIATRYIF3.82014-10-2411PREAI
Stigmatization of psychiatrists and general practitioners: results of an international surveyEUROPEAN ARCHIVES OF PSYCHIATRY AND CLINICAL NEUROSCIENCEIF3.72014-09-0544PREAI
Increased slow waves in electroencephalogram (EEG) but not daytime sleepiness in schizophrenic patients during antipsychotic treatmentEUROPEAN NEUROPSYCHOPHARMACOLOGYIF6.72013-10-010PREAI